)
Visual
test
Verve Therapeutics
Verve Therapeutics (VERV) investor relations material
Verve Therapeutics has been acquired by Eli Lilly and Company
Verve Therapeutics Goldman Sachs 46th Annual Global Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Goldman Sachs 46th Annual Global Healthcare Conference summary9 Jun, 2025
Strategic vision and clinical progress
Focus on one-time gene editing therapy for lifelong cholesterol reduction to address atherosclerotic cardiovascular disease, aiming for enduring efficacy where current therapies fall short.
HEART-2 trial of VERVE-102 showed up to 69% LDL reduction (mean 59%) at highest dose, with strong safety and tolerability across 14 patients.
Durability data from earlier product (VERVE-101) demonstrated sustained LDL lowering for two years post-infusion, supporting the one-dose future vision.
VERVE-102 uses a novel lipid nanoparticle delivery system with GalNAc ligand for liver targeting, improving safety and therapeutic index over VERVE-101.
Dose escalation continues to identify the optimal fixed dose, with a transition to fixed dosing planned for phase II later in the year.
Safety, durability, and regulatory outlook
No major safety issues observed with VERVE-102; no ALT or platelet elevations, and only one mild infusion reaction among 14 patients.
Durability of effect is supported by both preclinical and human data, with edits persisting beyond typical liver cell turnover, and potential for redosing if needed.
Long-term follow-up (15 years) is planned for all patients, with four to five years of data expected at registration.
Regulatory agencies are increasingly supportive of in vivo gene editing, with recent high-profile cases and policy statements highlighting openness to transformative therapies.
Market research, patient and physician perspectives
Surveys show strong openness among patients and cardiologists for a one-time gene editing therapy, especially among younger patients and those with genetic high cholesterol.
About a third of patients and 40% of cardiologists (for HeFH) prefer a one-time gene edit over daily pills or injections; 20% preference among ASCVD patients.
Payers may be more flexible on pricing due to large patient populations and low manufacturing costs, with potential for significant margin flexibility.
How does Verve's cost structure enable market access?
What is the rationale for fixed dosing in Phase II?
Compare Lilly's PCSK9 and LPA partnership models.
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Latest summaries
- TimeTickerHeadlineOpen
- DANSKE
Record core income and strong credit quality drove DKK 23.0bn net profit; 2026 outlook positive. - DANSKERecord core income, strong credit quality, and 100% profit distribution define 2025 results.
- 7211
Net sales and profits fell year-over-year, but recent earnings show gradual recovery. - 524742
Strong revenue and profit growth with robust margins and expanding global presence in Q3 FY26. - ANTHEM
Q3 FY26 saw robust revenue, profit growth, and capital increase post-IPO and ESOP allotments. - AFRY
Margin and utilization gains in Q4 offset lower sales and profit amid market challenges. - 8111
Sales and operating profit rose, but net profit fell on lower affiliate gains; outlook steady. - 7731
Large impairment in Digital Manufacturing and weak sales led to sharp losses and a weaker outlook. - 6370
Profits and sales rose, led by General Industry, with robust capital actions and a positive outlook. - 9312
Profits and dividends rose on strong domestic logistics, with improved financial stability.
Verve Therapeutics
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Verve Therapeutics Inc., founded in 2018, is a genetic medicines company focused on developing gene editing treatments for cardiovascular diseases. The company's flagship product, VERVE-101, is a single-course gene editing treatment designed to permanently inactivate the PCSK9 gene in the liver, with an aim to address cardiovascular conditions effectively. The company is headquartered in Cambridge, Massachusetts, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage